Emergent BioSolutions Stock Forecast, Price & News

-2.88 (-4.36 %)
(As of 04/22/2021 12:00 AM ET)
Today's Range
Now: $63.12
50-Day Range
MA: $85.15
52-Week Range
Now: $63.12
Volume1.77 million shs
Average Volume743,869 shs
Market Capitalization$3.38 billion
P/E Ratio20.30
Dividend YieldN/A
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response products and solutions for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers ACAM2000, a smallpox vaccine; BioThrax, an anthrax vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. The company also provides NARCAN for the emergency treatment of known or suspected opioid overdose; and Reactive Skin Decontamination Lotion Kit, a medical device to remove or neutralize chemical warfare agents from the skin. In addition, it offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccination; and Trobigard a combination drug-device auto injector product candidate. Further, the company is developing COVID-EIG and COVID-HIG potential treatments to COVID-19 disease; and FLU-IGIV for the treatment of Influenza A infection in hospitalized patients. Additionally, it provides contract development and manufacturing service that comprises development services, drug substance manufacturing, and drug product manufacturing in the pharmaceutical and biotechnology industries, as well as the governments and non-governmental organizations. The company has collaboration agreements with Novavax Inc.; and Johnson & Johnson. Emergent BioSolutions Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.
Emergent BioSolutions logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Year FoundedN/A



Sales & Book Value

Annual Sales$1.11 billion
Cash Flow$3.02 per share
Book Value$21.08 per share


Net Income$54.50 million


Market Cap$3.38 billion
Next Earnings Date4/29/2021 (Confirmed)


See More Headlines


Overall MarketRank

2.17 out of 5 stars

Medical Sector

29th out of 2,024 stocks

Pharmaceutical Preparations Industry

13th out of 771 stocks

Analyst Opinion: 3.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 3.1 5 -4 -3 -2 -1 -
-2.88 (-4.36 %)
(As of 04/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EBS News and Ratings via Email

Sign-up to receive the latest news and ratings for EBS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Emergent BioSolutions (NYSE:EBS) Frequently Asked Questions

Is Emergent BioSolutions a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Emergent BioSolutions in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Emergent BioSolutions stock.
View analyst ratings for Emergent BioSolutions
or view top-rated stocks.

What stocks does MarketBeat like better than Emergent BioSolutions?

Wall Street analysts have given Emergent BioSolutions a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Emergent BioSolutions wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Emergent BioSolutions' next earnings date?

Emergent BioSolutions is scheduled to release its next quarterly earnings announcement on Thursday, April 29th 2021.
View our earnings forecast for Emergent BioSolutions

How can I listen to Emergent BioSolutions' earnings call?

Emergent BioSolutions will be holding an earnings conference call on Thursday, April 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Emergent BioSolutions' earnings last quarter?

Emergent BioSolutions Inc. (NYSE:EBS) released its earnings results on Wednesday, February, 17th. The biopharmaceutical company reported $3.67 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $2.72 by $0.95. The biopharmaceutical company had revenue of $583 million for the quarter, compared to analyst estimates of $588.39 million. Emergent BioSolutions had a trailing twelve-month return on equity of 26.68% and a net margin of 12.50%.
View Emergent BioSolutions' earnings history

How has Emergent BioSolutions' stock price been impacted by Coronavirus (COVID-19)?

Emergent BioSolutions' stock was trading at $53.03 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, EBS stock has increased by 19.0% and is now trading at $63.12.
View which stocks have been most impacted by COVID-19

What guidance has Emergent BioSolutions issued on next quarter's earnings?

Emergent BioSolutions issued an update on its FY 2021 After-Hours earnings guidance on Thursday, February, 18th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.95-2.05 billion, compared to the consensus revenue estimate of $1.93 billion.

What price target have analysts set for EBS?

7 analysts have issued 12-month target prices for Emergent BioSolutions' stock. Their forecasts range from $90.00 to $150.00. On average, they expect Emergent BioSolutions' share price to reach $113.67 in the next twelve months. This suggests a possible upside of 80.1% from the stock's current price.
View analysts' price targets for Emergent BioSolutions
or view top-rated stocks among Wall Street analysts.

Who are Emergent BioSolutions' key executives?

Emergent BioSolutions' management team includes the following people:
  • Mr. Fuad El-Hibri, Founder & Exec. Chairman (Age 63, Pay $1.2M)
  • Mr. Robert G. Kramer, CEO, Pres & Exec. Director (Age 64, Pay $2.13M)
  • Mr. Richard S. Lindahl, Exec. VP, CFO & Treasurer (Age 57, Pay $1.02M)
  • Mr. Atul Saran, Exec. VP of Corp. Devel., Gen. Counsel & Corp. Sec. (Age 48, Pay $983.57k)
  • Mr. Adam R. Havey, Exec. VP of Bus. Operations (Age 50, Pay $1M)
  • Mr. Sean M. Kirk, Exec. VP of Manufacturing & Technical Operations (Age 46)
  • Mr. Howard Anderson, Sr. VP & Chief Information Officer
  • Mr. Robert G. Burrows, VP of Investor Relations
  • Ms. Laura K. Kennedy, Sr. VP and Chief Ethics & Compliance Officer
  • Ms. Lynn Kieffer, VP of Corp. Communications

What is Bob Kramer's approval rating as Emergent BioSolutions' CEO?

38 employees have rated Emergent BioSolutions CEO Bob Kramer on Glassdoor.com. Bob Kramer has an approval rating of 74% among Emergent BioSolutions' employees.

Who are some of Emergent BioSolutions' key competitors?

What other stocks do shareholders of Emergent BioSolutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Emergent BioSolutions investors own include NVIDIA (NVDA), salesforce.com (CRM), Novavax (NVAX), Advanced Micro Devices (AMD), Square (SQ), Netflix (NFLX), Gilead Sciences (GILD), PayPal (PYPL), Johnson & Johnson (JNJ) and AbbVie (ABBV).

What is Emergent BioSolutions' stock symbol?

Emergent BioSolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."

Who are Emergent BioSolutions' major shareholders?

Emergent BioSolutions' stock is owned by a variety of retail and institutional investors. Top institutional investors include Scout Investments Inc. (0.28%), Retirement Systems of Alabama (0.26%), Central Bank & Trust Co. (0.09%), Hillsdale Investment Management Inc. (0.07%), Louisiana State Employees Retirement System (0.02%) and First Business Financial Services Inc. (0.02%). Company insiders that own Emergent BioSolutions stock include Adam Havey, Fuad El-Hibri, George A Joulwan, Kathryn C Zoon, Louis W Sullivan, Robert Kramer, Ronald Richard, Sue Bailey and Zsolt Harsanyi.
View institutional ownership trends for Emergent BioSolutions

Which major investors are selling Emergent BioSolutions stock?

EBS stock was sold by a variety of institutional investors in the last quarter, including Hillsdale Investment Management Inc., Scout Investments Inc., Coastal Investment Advisors Inc., Argus Investors Counsel Inc., Pacer Advisors Inc., State of Alaska Department of Revenue, and Private Capital Group LLC. Company insiders that have sold Emergent BioSolutions company stock in the last year include Fuad El-Hibri, George A Joulwan, Louis W Sullivan, Robert Kramer, Ronald Richard, Sue Bailey, and Zsolt Harsanyi.
View insider buying and selling activity for Emergent BioSolutions
or view top insider-selling stocks.

Which major investors are buying Emergent BioSolutions stock?

EBS stock was bought by a variety of institutional investors in the last quarter, including Harbour Capital Advisors LLC, Juncture Wealth Strategies LLC, Central Bank & Trust Co., First Business Financial Services Inc., Landsberg Bennett & Dubbaneh LLC, GPS Wealth Strategies Group LLC, Louisiana State Employees Retirement System, and Retirement Systems of Alabama.
View insider buying and selling activity for Emergent BioSolutions
or or view top insider-buying stocks.

How do I buy shares of Emergent BioSolutions?

Shares of EBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Emergent BioSolutions' stock price today?

One share of EBS stock can currently be purchased for approximately $63.12.

How much money does Emergent BioSolutions make?

Emergent BioSolutions has a market capitalization of $3.38 billion and generates $1.11 billion in revenue each year. The biopharmaceutical company earns $54.50 million in net income (profit) each year or $2.91 on an earnings per share basis.

How many employees does Emergent BioSolutions have?

Emergent BioSolutions employs 2,200 workers across the globe.

What is Emergent BioSolutions' official website?

The official website for Emergent BioSolutions is www.emergentbiosolutions.com.

Where are Emergent BioSolutions' headquarters?

Emergent BioSolutions is headquartered at 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879.

How can I contact Emergent BioSolutions?

Emergent BioSolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The biopharmaceutical company can be reached via phone at 240-631-3200 or via email at [email protected]

This page was last updated on 4/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.